Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.

By E. Horwitz, K. Blanc, M. Dominici, Ingo Mueller, I. Slaper-Cortenbach, F. Marini, R. Deans, D. Krause, A. Keating. Cytotherapy, 2005

2,027 citations recorded by the source corpus.

Subfields: Genetics, Physiology, Surgery

View Paper: https://www.semanticscholar.org/paper/9c41bc2f2a022f724a9f921c8b48752544ef61df

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. A. Caplan
2. P. Robey
3. P. Bianco
4. P. Simmons
5. A. Keating
6. L. Meirelles
7. D. Prockop
8. J. Karp

In Physiology

1. A. Caplan
2. P. Bianco
3. P. Robey

In Surgery

1. A. Caplan
2. A. Keating
3. J. Karp
4. Grace Sock Leng Teo

Citations in the corpus

• Mesenchymal stem cells: revisiting history, concepts, and assays. (2008, background): “…started to emerge (Sacchetti et al., 2007) and does indeed support the concept that such cells include a bona fide stem cell, and it also addresses the previous lack of direct experimental evidence for the ability of stromal cells to self-renew (Dominici et al., 2006; Horwitz et al., 2005).”
• Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells (2012, positive): “…cell population, as selected by rapid plastic adherence, implying that this cell population is heterogeneously composed of bona fide stem cells, their progeny (with multilineage differentiation potential, but without salient characteristics of stem cells), and possibly senescent cells [5,7,8].”
• Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process (2008, background): “Reliable markers for the definition of the multipotent fraction have not yet been defined and hence these cells have alternatively been named mesenchymal stromal cells [5].”
• Mesenchymal stem cells in health and disease (2008, background): “It is now accepted that most bone-marrow-derived progenitor stromal cells can be considered, after in vitro proliferation, to be MSC”
• The elusive nature and function of mesenchymal stem cells (2011, neutral): “The International Society for Cellular Therapy, Vancouver, Canada, has recommended the use of the name multipotent mesenchymal stromal cell (also abbreviated to MSCs, although not in this Opinion article) for the in vitro cultured cells, restricting the term stem cell to designate the proposed in”
• Leptin Receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow (2014, neutral): “…as nonhematopoietic, plastic-adherent, col- ony-forming cells, referred to as colony-forming unit-fibroblasts (CFU-Fs), that can differentiate into osteogenic, chondrogenic, and adipogenic progeny (Bianco et al., 2008; Friedenstein et al., 1970; Horwitz et al., 2005; Pittenger et al., 1999).”
• Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? (2016, background): “a common progenitor cell with adipocytes, bone marrow mesenchymal stem cells (MSCs).(2,3) The imbalance between”
• Bone substitutes in orthopaedic surgery: from basic science to clinical practice (2014, neutral): “); hence they are also named ‘‘stromal stem cells’’ [180].”